2020.07.09 02:20
No. | Subject | Date | Author | Last Update | Views |
---|---|---|---|---|---|
Notice | How to write your comments onto a webpage [2] | 2016.07.06 | 운영자 | 2016.11.20 | 18193 |
Notice | How to Upload Pictures in webpages | 2016.07.06 | 운영자 | 2018.10.19 | 32348 |
Notice | How to use Rich Text Editor [3] | 2016.06.28 | 운영자 | 2018.10.19 | 5925 |
Notice | How to Write a Webpage | 2016.06.28 | 운영자 | 2020.12.23 | 43840 |
623 | [Medical]The 2017 Guidelines for Hypertension | 2018.06.26 | 이한중*65 | 2018.06.26 | 8723 |
622 | ♥ 고혈압치료: 수축기 혈압 140에서 130, 심혈관질환 감소 [5] | 2010.07.14 | 이종구*57 | 2010.07.14 | 8535 |
621 | ♥ 비만과 건강-2 [1] | 2009.11.09 | 이종구*57 | 2009.11.09 | 8521 |
620 | ♥ 고혈압치료에서 가장 중요한 것은 혈압? 약물의 선택? | 2009.12.21 | 이종구*57 | 2009.12.21 | 8475 |
619 | [Medical Column] 협심증의 진단 1 | 2012.12.10 | 이종구*57 | 2012.12.10 | 8461 |
618 | ♥ 이뇨제: 당뇨병 발생률 증가, 심혈관질환 사망률 감소 [1] | 2010.07.07 | 이종구*57 | 2010.07.07 | 8446 |
617 | Food or Insulin for Some Americans [1] | 2020.04.23 | 온기철*71 | 2020.04.23 | 8438 |
616 | ♥ Clopidogrel의 임상적 적용 [1] | 2010.06.21 | 이종구*57 | 2010.06.21 | 8437 |
615 | ♥ 뇌졸중 -1 [1] | 2009.08.11 | 이종구*57 | 2009.08.11 | 8392 |
614 | ♥ 신형 혈관확장제(Darusentan)가 난치성 고혈압에 효과적 | 2010.08.25 | 이종구*57 | 2010.08.25 | 8370 |
613 | ♥ 80세 이상 노인에서 고혈압을 적극적으로 치료한다 | 2010.07.28 | 이종구*57 | 2010.07.28 | 8335 |
612 | ♥ 고지혈증 | 2010.04.28 | 이종구*57 | 2010.04.28 | 8237 |
611 | ♥ 생선과 Omega-3지방산(EPA, DHA)은 관상동맥질환에서 사망률을 감소 [1] | 2010.08.30 | 이종구*57 | 2010.08.30 | 8205 |
610 | ♥ 중성지방과 대사증후군 [1] | 2010.06.23 | 이종구*57 | 2010.06.23 | 8182 |
609 | ♥ 뇌졸증-3 | 2009.08.24 | 이종구*57 | 2009.08.24 | 8174 |
608 | ♥ 고혈압 치료는 발기부전을 유발하는가? [1] | 2010.07.21 | 이종구*57 | 2010.07.21 | 8153 |
607 | ♥ 관상동맥확장술(PCI)과 우회로수술(CABG)이후의 약물치료 | 2010.04.05 | 이종구*57 | 2010.04.05 | 8075 |
606 | ♥ 심부전증 | 2010.06.02 | 이종구*57 | 2010.06.02 | 8069 |
605 | 영국 고혈압학회가 제시하는 고혈압치료의 새로운 지침 | 2009.11.23 | 이종구*57 | 2009.11.23 | 7939 |
604 | ♥ 약물방출 스텐트는 금속에 비해 혈전증과 심근경색증을 증가 가능 | 2010.02.15 | 이종구*57 | 2010.02.15 | 7928 |
Baloxavir Marboxil for Prophylaxis against Influenza in Household Contacts
List of authors.
Abstract
BACKGROUND
Baloxavir marboxil (baloxavir) is a polymerase acidic protein (PA) endonuclease inhibitor with clinical efficacy in the treatment of uncomplicated influenza, including in outpatients at increased risk for complications. The postexposure prophylactic efficacy of baloxavir in the household setting is unclear.
METHODS
We conducted a multicenter, double-blind, randomized, placebo-controlled trial to evaluate the postexposure prophylactic efficacy of baloxavir in household contacts of index patients with confirmed influenza during the 2018–2019 season in Japan. The participants were assigned in a 1:1 ratio to receive either a single dose of baloxavir or placebo. The primary end point was clinical influenza, as confirmed by reverse-transcriptase–polymerase-chain-reaction testing, over a period of 10 days. The occurrence of baloxavir-selected PA substitutions associated with reduced susceptibility was assessed.
RESULTS
A total of 752 household contacts of 545 index patients were randomly assigned to receive baloxavir or placebo. Among the index patients, 95.6% had influenza A virus infection, 73.6% were younger than 12 years of age, and 52.7% received baloxavir. Among the participants who could be evaluated (374 in the baloxavir group and 375 in the placebo group), the percentage in whom clinical influenza developed was significantly lower in the baloxavir group than in the placebo group (1.9% vs. 13.6%) (adjusted risk ratio, 0.14; 95% confidence interval [CI], 0.06 to 0.30; P<0.001). Baloxavir was effective in high-risk, pediatric, and unvaccinated subgroups of participants. The risk of influenza infection, regardless of symptoms, was lower with baloxavir than with placebo (adjusted risk ratio, 0.43; 95% CI, 0.32 to 0.58). The incidence of adverse events was similar in the two groups (22.2% in the baloxavir group and 20.5% in the placebo group). In the baloxavir group, the viral PA substitutions I38T/M or E23K were detected in 10 (2.7%) and 5 (1.3%) participants, respectively. No transmission of these variants from baloxavir-treated index patients to participants in the placebo group was detected; however, several instances of transmission to participants in the baloxavir group could not be ruled out.
CONCLUSIONS
Single-dose baloxavir showed significant postexposure prophylactic efficacy in preventing influenza in household contacts of patients with influenza. (Funded by Shionogi; Japan Primary Registries Network number, JapicCTI-184180.)(NEJM July 8, 2020)